Glaukos reports record Q2 sales $95.7M (+19% YoY), raises FY2024 guidance

GLAUKOS Corp

2024-Q2 EPS reported -$1.82 revenue$181,312,000

Record net sales of $95.7M, up 19% reported / 20% constant currency YoY.
Glaucoma segment sales $75.9M (+23% YoY); Corneal Health $19.8M (+7% YoY).
GAAP net loss $53.9M ($1.06 loss per share) vs $32.8M ($0.68) in Q2 2023.
Non-GAAP net loss $26.3M ($0.52 loss per share) improved from $26.6M ($0.55) prior year.
FY2024 net sales guidance raised to $370M–$376M from $357M–$365M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.